Ian J Neeland, Usman Salahuddin, Darren K McGuire. Expert Opin Drug Saf 2016
Times Cited: 8
Times Cited: 8
Times Cited
Times Co-cited
Similarity
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
37
Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.
André J Scheen. Clin Pharmacokinet 2014
André J Scheen. Clin Pharmacokinet 2014
37
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
37
25
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
25
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
25
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
25
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
25
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
25
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Ralph A Defronzo. Diabetes 2009
Ralph A Defronzo. Diabetes 2009
25
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
25
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr Rev 2011
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr Rev 2011
25
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
25
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
25
Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
R Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan, Suhaj Abdulsalim. Postgrad Med 2017
R Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan, Suhaj Abdulsalim. Postgrad Med 2017
25
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
25
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
25
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
25
A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus.
Gita Chawla, Krishna Kr Chaudhary. Diabetes Metab Syndr 2019
Gita Chawla, Krishna Kr Chaudhary. Diabetes Metab Syndr 2019
25
Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes.
Uche Anadu Ndefo, Nicole O Anidiobi, Efrah Basheer, Angie T Eaton. P T 2015
Uche Anadu Ndefo, Nicole O Anidiobi, Efrah Basheer, Angie T Eaton. P T 2015
25
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Katherine R Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner,[...]. Diabetes Care 2022
Katherine R Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner,[...]. Diabetes Care 2022
66
Glycemic exposure, glycemic control, and metabolic karma in diabetic complications.
Merlin C Thomas. Adv Chronic Kidney Dis 2014
Merlin C Thomas. Adv Chronic Kidney Dis 2014
12
Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy.
Manish Mishra, Qing Zhong, Renu A Kowluru. Invest Ophthalmol Vis Sci 2014
Manish Mishra, Qing Zhong, Renu A Kowluru. Invest Ophthalmol Vis Sci 2014
12
Antiplatelet aggregation and endothelial protection of I4, a new synthetic anti-diabetes sulfonylurea compound.
Lingman Ma, Na Lu, Guanzhong Wu. Platelets 2015
Lingman Ma, Na Lu, Guanzhong Wu. Platelets 2015
20
Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis.
Vardhman K Rakyan, Huriya Beyan, Thomas A Down, Mohammed I Hawa, Siarhei Maslau, Deeqo Aden, Antoine Daunay, Florence Busato, Charles A Mein, Burkhard Manfras,[...]. PLoS Genet 2011
Vardhman K Rakyan, Huriya Beyan, Thomas A Down, Mohammed I Hawa, Siarhei Maslau, Deeqo Aden, Antoine Daunay, Florence Busato, Charles A Mein, Burkhard Manfras,[...]. PLoS Genet 2011
12
Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes.
Francesco Prattichizzo, Angelica Giuliani, Artan Ceka, Maria Rita Rippo, Anna Rita Bonfigli, Roberto Testa, Antonio Domenico Procopio, Fabiola Olivieri. Clin Epigenetics 2015
Francesco Prattichizzo, Angelica Giuliani, Artan Ceka, Maria Rita Rippo, Anna Rita Bonfigli, Roberto Testa, Antonio Domenico Procopio, Fabiola Olivieri. Clin Epigenetics 2015
12
Targeting chromatin remodeling to prevent cardiovascular disease in diabetes.
Sarah Costantino, Francesco Paneni, Francesco Cosentino. Curr Pharm Biotechnol 2015
Sarah Costantino, Francesco Paneni, Francesco Cosentino. Curr Pharm Biotechnol 2015
12
Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.
Matthew C Riddle. Diabetes Care 2010
Matthew C Riddle. Diabetes Care 2010
12
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.
Caroline S Fox, Sherita Hill Golden, Cheryl Anderson, George A Bray, Lora E Burke, Ian H de Boer, Prakash Deedwania, Robert H Eckel, Abby G Ershow, Judith Fradkin,[...]. Diabetes Care 2015
Caroline S Fox, Sherita Hill Golden, Cheryl Anderson, George A Bray, Lora E Burke, Ian H de Boer, Prakash Deedwania, Robert H Eckel, Abby G Ershow, Judith Fradkin,[...]. Diabetes Care 2015
12
Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway.
Shuzhi Zhao, Jun Li, Na Wang, Bingqing Zheng, Tao Li, Qing Gu, Xun Xu, Zhi Zheng. Mol Med Rep 2015
Shuzhi Zhao, Jun Li, Na Wang, Bingqing Zheng, Tao Li, Qing Gu, Xun Xu, Zhi Zheng. Mol Med Rep 2015
12
Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications.
Poojitha Rajasekar, Christina L O'Neill, Lydia Eeles, Alan W Stitt, Reinhold J Medina. J Diabetes Res 2015
Poojitha Rajasekar, Christina L O'Neill, Lydia Eeles, Alan W Stitt, Reinhold J Medina. J Diabetes Res 2015
12
Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study.
Marco Comaschi, Carlo Coscelli, Domenico Cucinotta, Pierluigi Malini, Enzo Manzato, Antonio Nicolucci. Nutr Metab Cardiovasc Dis 2005
Marco Comaschi, Carlo Coscelli, Domenico Cucinotta, Pierluigi Malini, Enzo Manzato, Antonio Nicolucci. Nutr Metab Cardiovasc Dis 2005
12
Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion.
Tasnim Dayeh, Petr Volkov, Sofia Salö, Elin Hall, Emma Nilsson, Anders H Olsson, Clare L Kirkpatrick, Claes B Wollheim, Lena Eliasson, Tina Rönn,[...]. PLoS Genet 2014
Tasnim Dayeh, Petr Volkov, Sofia Salö, Elin Hall, Emma Nilsson, Anders H Olsson, Clare L Kirkpatrick, Claes B Wollheim, Lena Eliasson, Tina Rönn,[...]. PLoS Genet 2014
12
Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
12
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
Yuji Ishibashi, Takanori Matsui, Sayaka Maeda, Yuichiro Higashimoto, Sho-ichi Yamagishi. Cardiovasc Diabetol 2013
Yuji Ishibashi, Takanori Matsui, Sayaka Maeda, Yuichiro Higashimoto, Sho-ichi Yamagishi. Cardiovasc Diabetol 2013
12
Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.
John M Lachin, Neil H White, Dean P Hainsworth, Wanjie Sun, Patricia A Cleary, David M Nathan. Diabetes 2015
John M Lachin, Neil H White, Dean P Hainsworth, Wanjie Sun, Patricia A Cleary, David M Nathan. Diabetes 2015
12
Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.
Taina K Mattila, Anthonius de Boer. Drugs 2010
Taina K Mattila, Anthonius de Boer. Drugs 2010
12
Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
Ralph A DeFronzo. Am J Med 2010
Ralph A DeFronzo. Am J Med 2010
12
Hypothesis: the 'metabolic memory', the new challenge of diabetes.
M A Ihnat, J E Thorpe, A Ceriello. Diabet Med 2007
M A Ihnat, J E Thorpe, A Ceriello. Diabet Med 2007
12
Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
Daisuke Katagiri, Yoshifumi Hamasaki, Kent Doi, Koji Okamoto, Kousuke Negishi, Masaomi Nangaku, Eisei Noiri. J Am Soc Nephrol 2013
Daisuke Katagiri, Yoshifumi Hamasaki, Kent Doi, Koji Okamoto, Kousuke Negishi, Masaomi Nangaku, Eisei Noiri. J Am Soc Nephrol 2013
12
Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice.
Joanne S Allard, Evelyn J Perez, Koji Fukui, Priscilla Carpenter, Donald K Ingram, Rafael de Cabo. Behav Brain Res 2016
Joanne S Allard, Evelyn J Perez, Koji Fukui, Priscilla Carpenter, Donald K Ingram, Rafael de Cabo. Behav Brain Res 2016
12
10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
12
DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes.
Tina Rönn, Charlotte Ling. Epigenomics 2015
Tina Rönn, Charlotte Ling. Epigenomics 2015
12
Metabolic regulation of neuronal plasticity by the energy sensor AMPK.
Wyatt B Potter, Kenneth J O'Riordan, David Barnett, Susan M K Osting, Matthew Wagoner, Corinna Burger, Avtar Roopra. PLoS One 2010
Wyatt B Potter, Kenneth J O'Riordan, David Barnett, Susan M K Osting, Matthew Wagoner, Corinna Burger, Avtar Roopra. PLoS One 2010
12
Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Khalid Alrasadi, Zuhier Awan, Khalid Alwaili, Isabelle Ruel, Anouar Hafiane, Larbi Krimbou, Jacques Genest. Am J Cardiol 2008
Khalid Alrasadi, Zuhier Awan, Khalid Alwaili, Isabelle Ruel, Anouar Hafiane, Larbi Krimbou, Jacques Genest. Am J Cardiol 2008
12
Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association.
Judith G Regensteiner, Sherita Golden, Amy G Huebschmann, Elizabeth Barrett-Connor, Alice Y Chang, Deborah Chyun, Caroline S Fox, Catherine Kim, Nehal Mehta, Jane F Reckelhoff,[...]. Circulation 2015
Judith G Regensteiner, Sherita Golden, Amy G Huebschmann, Elizabeth Barrett-Connor, Alice Y Chang, Deborah Chyun, Caroline S Fox, Catherine Kim, Nehal Mehta, Jane F Reckelhoff,[...]. Circulation 2015
12
Intensive glucose control did not prevent important complications in type 2 diabetes.
Victor M Montori, German Malaga. Evid Based Med 2008
Victor M Montori, German Malaga. Evid Based Med 2008
50
miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway.
Shuzhi Zhao, Tao Li, Jun Li, Qianyi Lu, Changjing Han, Na Wang, Qinghua Qiu, Hui Cao, Xun Xu, Haibing Chen,[...]. Diabetologia 2016
Shuzhi Zhao, Tao Li, Jun Li, Qianyi Lu, Changjing Han, Na Wang, Qinghua Qiu, Hui Cao, Xun Xu, Haibing Chen,[...]. Diabetologia 2016
12
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.